@entity1611 ( @entity1611 ) is one of the key growth factors regulating @entity5 angiogenesis and thus it is one of the primary targets for antiangiogenic therapy. The long-term effects of @entity1611 include induction of proliferation and migration of endothelial cells, tube formation and maintenance of the immature capillaries. The early effects of @entity1611 include vasodilation and increased permeability. We hypothesize that the early responses to @entity1611 can serve to develop a quantitative measure of the activity of @entity1611 , and therefore may be applicable for monitoring the efficacy of systemic suppression of @entity1611 signaling during antiangiogenic therapy. For that end we tested the ability of MRI and fluorescence microscopy to detect the early response to intradermal @entity1655 in @entity19 . @entity1611 -induced local vasodilation and increased permeability was detected by intravenous administration of macromolecular @entity70433 (23) 30 min after intradermal administration of @entity1611 . Contrast leak showed saturation kinetics. Delayed contrast administration (90 min after intradermal administration of @entity1611 ) resulted in low contrast leak and demonstrated that the saturation kinetics is not due to contrast equilibration between plasma and the interstitial space, but rather is due to suppression of vascular permeability. Permeability was restored by a second bolus of @entity1611 , showing that the saturation kinetics is primarily due to inactivation of the growth factor. Confocal microscopy of fluorescent BSA- @entity2823 confirmed the permeability changes monitored by MRI. Moreover, confocal microscopy showed efficient lymphatic uptake of the extravasated contrast material specifically in regions of @entity1611 induced @entity2915 .

MRI and fluorescence microscopy of the acute vascular response to XXXX : vasodilation, @entity2915 and lymphatic uptake, followed by rapid inactivation of the growth factor.

@entity19 :: ('10090', 'Species') :: ['nude mice'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumor'] @entity1655 :: ('MESH:C467484', 'Chemical') :: ['VEGF165'] @entity2823 :: ('MESH:D016650', 'Chemical') :: ['FITC'] @entity2915 :: ('MESH:D006948', 'Disease') :: ['hyper-permeability'] @entity1611 :: ('22339(Tax:10090)', 'Gene') :: ['Vascular endothelial growth factor', 'VEGF'] @entity70433 :: ('MESH:C513815', 'Chemical') :: ['biotin-BSA-GdDTPA']
@entity1655 :: (MESH:C467484,Chemical) :: ['VEGF165']
